Japan Tobacco Inc. said Wednesday it has acquired the rights to develop and market the kidney drug Zerenex in Japan from U.S. pharmaceutical maker Keryx Biopharmaceuticals Inc.
JT and its drug unit Torii Pharmaceutical Co. will pay as much as $100 million to the U.S. company for the rights. The two companies will also pay royalties once the drug begins selling on the market, Tokyo-based JT said in a statement distributed at the Tokyo Stock Exchange.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.